Citations

Clear

362 citation(s) found for "Shaw, L J".

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
Silvey, Scott , Choudhury, Ashok , Kamath, Patrick S. , Wong, Florence , Hayes, P C, Seto, Wai‐Kay , Singhal, Garima, Jothimani, Dinesh , Asrani, Sumeet, Gadano, Adrián , Dinçer, Dinc , Adebayo, Daneille, Doyle, Adam, Debzi, Nabil , Shaw, Jawaid , Barutçu, Sezgin , Lah, Ponan Claude Regis, Duarte‐Rojo, Andrés , Turan, Dilara , Wang, Lei, Velazquez, René Malé, Aghayaeva, Sevda, Córdova-Gallardo, J, Xu, Bin, Gao, Haibing , Elangovan, Harendran, Fung, James, Rajorya, Neil, Wang, X I A O Y U, Katchman, Helena , Jiang, Yongfang, Thanapirom, Kessarin , Eapen, CE, Dhiman, Radha K. , Lu, Mingqin, Su, Minghua , Hueso, Sarai Gonzalez, Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping, MacQuillan, Gerry, Pereira, Gustavo, Reddy, K. Rajender , Topazian, Mark, Torre, A Ullate De La, Silva, Mario, Bush, Brian J., Bajaj, Jasmohan S. , Chaudhary, Ashok , Xie, Qing , Wong, Florence , Arora, Umang , Gadano, Adrian , Dincer, Dinc , Velarde-Ruiz Velasco, José Antonio , Kulkarni, Anand V , Shaw, Jawaid , Desalgn, Hailemicheal , Bettinger, Dominik , Regis Lah, Ponan Claude , Duarte-Rojo, Andres , Turan, Dilara , Zheng, Xin , Demirtas, Coskun , Liu, Chenghai , Cordova-Gallardo, Jacqueline , Nagral, Aabha , Gao, Haibing , Katchmann, Helena , Praharaj, Dibyalochan , Mahadeva, Sanjiv , Eapen, C E , Dhiman, Radha K , Lu, Mingqin , Arrese, Marco , Su, Minghua , Hueso, Sarai Gonzalez , Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping , Taneja, Sunil , Sonavane, Amey , Saraya, Anoop , Gofton, Cameron , Pereira, Gustavo , Rajender Reddy, K , Sarin, Shiv Kumar , Cao, Zhujun , Topazian, Mark D , Idilman, Ramazan , Torre, Aldo , George, Jacob , BUSH, BRIAN J. , Bajaj, Jasmohan S , Seto, Wai-Kay , Singhal, Garima, Asrani, Sumeet K. , Farias, Alberto Queiróz , Velasco, J.A. Velarde-Ruiz , Kulkarni, Anand V. , Desalegn, Hailemichael , Karasu, Zeki A. , Fung, James , Rajoriya, Neil , Zheng, Katina , Arrese, Marco , Zhu, Chuanwu , Taneja, Sunil , Aravinthan, Aloysious Dominic , MacQuillan, Gerry C., Idılman, Ramazan , George, Jacob , Alvares-da-Silva, Mario Reis

Mayo Clinic

American Journal of Gastroenterology | April 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004031 | PMID 42043180 Get It

INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025)
Kanoria, Shaveta , Miller, Melanie J., Aisen, Paul S., Beckett, Laurel A., Green, Robert C., Harvey, Danielle J., Jack, Clifford R., Jagust, William, Lee, Edward B., Nho, Kwangsik, Nosheny, Rachel, Okonkwo, Ozioma C., Perrin, Richard J., Petersen, Ronald C., Saykin, Andrew J., Shaw, Leslie M., Toga, Arthur W., Tosun, Duygu, Landau, Susan M., Weiner, Michael W. , Initiative, for the Alzheimer's Disease Neuroimaging, Harvey, Danielle , Weiner, Michael W , Harvey, Danielle J , Veitch, Dallas P. , Miller, Melanie J. , Aisen, Paul , Beckett, Laurel , Green, Robert C. , Jack, Clifford R. , Jagust, William J. , Lee, Edward B. , Nho, Kwangsik T. , Nosheny, Rachel, Perrin, Richard J. , Petersen, Ronald C. , Mindt, Mónica Rivera , Saykin, Andrew J. , Shaw, Leslie M. , Toga, Arthur W. , Landau, Susan , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | April 16, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71353 | PMID 41988903 Get It

Abstract Alzheimer's disease (AD) continues to pose a major public health challenge. Since its launch in 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has played a pivotal role in advancing the field by providing a comprehensive, open‐access, longitudinal dataset that integrates neuroimaging, biomarker, genetic, and clinical data related to AD. We used standard literature search methods to identify ∼1830 publications from 2023 to mid‐2025 that used ADNI data or samples. This review highlights key ADNI studies with direct clinical applications. We describe how these have impacted the development and validation of plasma biomarkers, improved clinical trials, assessed AD therapies, and developed methods for diagnosis and prediction using clinical, fluid, and imaging biomarkers. These contributions are underlain by an improved understanding of biological mechanisms of disease progression in AD and highlight ADNI's central role in advancing translational research and accelerating progress toward more effective, individualized care for patients with AD.
Bringing Medical Care to the Streets: Lessons Learned in Launching a Street Medicine Outreach
Shaw, Christine , Ali, Hanin, Palisch, Chase, Weaver, Catherine, Shufflebarger, Erin F , Weaver, Catherine M

Mayo Clinic

AEM Education and Training | April 16, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/aet2.70161 | PMID 42005837 Get It

ABSTRACT Background Street Medicine, where healthcare is provided in non‐traditional settings, provides care to people experiencing homelessness (PEH). Street medicine has been shown to improve patients' health and decrease Emergency Department visits, making it a cost effective way to provide medical care to PEH. Methods This paper is based on the SAEM25 didactic session as conducted in Philadelphia, where a panel of providers who are directly involved in street medicine clinics shared their experiences and perspectives on the various designs in practice. These topics included key logistical challenges and solutions, barriers to care and trust building, strategies for fostering sustainable partnerships with community organizations, and options for medical student or resident involvement. Results The design and unique approach of four different universities across the country was compared and contrasted by a panel of experts, all with experiences working directly with PEH. There are similarly identified barriers to providing care to PEH including location and transportation, financial and food insecurity, and trust between the community and the healthcare system. Conclusion There are multiple options that exist to provide a framework to create a clinic to support populations of PEH.
Trends in Blood Pressure Control During the COVID‐19 Pandemic: A Study of 17 US Health Systems in the National Patient‐Centered Clinical Research Network Blood Pressure Control Laboratory
Chamberlain, Alanna M. , Cooper‐DeHoff, Rhonda M. , Fontil, Valy , Park, Soo , Shaw, Kathryn M., Smith, Myra C., Carton, Thomas W. , O'Brien, Emily C, Modrow, Madelaine Faulkner , Wozniak, Gregory , Smith, Steven M., Kappelman, M. D., Ford, D. Patrick, Williams, David A. , VanWormer, Jeffrey J. , Cowell, Lindsay G., Taylor, Bradley W., Chrischilles, EA, Carton, Thomas , O'Brien, Emily , Faulkner Modrow, Madelaine , Rakotz, Michael , Smith, Steven M , Kappelman, Michael D , Ford, Daniel E , Williams, David A , Reynolds Geary, Carol , Litvin, Cara , VanWormer, Jeffrey J , Mosa, Abu Saleh Mohammad , Taylor, Bradley , Chrischilles, Elizabeth A , Pletcher, Mark J , Chamberlain, Alanna M , Cooper‐DeHoff, Rhonda M. , Fontil, Valy , Park, Soo , Shaw, Kathryn M., O’Brien, Emily C. , Rakotz, Michael , Kappelman, Michael D. , Geary, Carol , Taylor, Bradley , Pletcher, Mark J.

Mayo Clinic

Journal of the American Heart Association | April 7, 2026 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/jaha.125.045694 | PMID 41944158 Get It

Background Reductions in blood pressure (BP) control among patients with hypertension were observed early in the COVID‐19 pandemic. The degree to which BP control may have returned to prepandemic levels is unknown. Methods Individuals aged 18 to 85 years with hypertension from 17 health systems participating in the National Patient‐Centered Clinical Research Network were identified using electronic health record data collected as part of routine care. BP control (percentage of patients whose most recent BP measurement was <140/<90 mm Hg) was estimated in a series of 12‐month rolling measurement periods from 2017 through 2022 (January 1, 2017 through December 31, 2017; April 1, 2017 through March 31, 2018; … January 1, 2022 through December 31, 2022). Differences in average BP control between 2022 (January 1, 2022 through December 31, 2022) and 2019 (January 1, 2019 through December 31, 2019) were estimated overall (adjusted for age, sex, and race and ethnicity) and by race and ethnicity (adjusted for age and sex). Results Our sample included 1 193 314 persons with hypertension in 2019 (48.9% aged 65–85 years, 52.9% men, 66.2% non‐Hispanic White) and 1 499 418 individuals in 2022 (50.6% aged 65–85 years, 47.1% men, 62.7% non‐Hispanic White). The weighted average BP control dropped from 65.3% in 2019 to 61.8% in 2020 and then partially recovered to 62.6% in 2022 (adjusted mean difference, −2.6 percentage points [95% CI, −5.0 to −0.2]). Non‐Hispanic Asian individuals experienced the largest temporal drop in BP control, declining from 68.4% in 2019 to 63.9% in 2022. Conclusions BP control was disrupted during the COVID‐19 pandemic and had not fully rebounded to prepandemic levels by the end of 2022. Continued surveillance is needed to determine whether the decline in BP control will persist and will result in future adverse cardiovascular events.
Abstract 2740: Applications of large language models to CAR-T cell therapy clinical data using Google cloud computing.
Jankowski, Matthew, Corraes, Andre de Menezes Silva, Gupta, Malvika , Shaw, Monica, Iqbal, Madiha , Chhabra, Saurabh, McLean, Jody, Riester, Kim R., Joseph, Kayla, Tan, Melinda, Ross, Holly, Barnett, Cleyonia, Carter, Sylvia L., Girmay, Semy, Wolan, Rachel M., Ramsey, Milana, Downhour, Christian, Morgan, Kristy, Sibley, Shae, Rushing, Erica C., Holmes, Lucy , Burgstahler, Allison R., Ansell, Stephen M., Hathcock, Matthew, Bruno, Ramona L., Johnston, Patrick B., Paludo, J., Lin, Yi, Guzman, Emmanuel Contreras , Jankowski, Matthew, Corraes, Andre De Menezes Silva , Hilal, Talal , Chhabra, Saurabh , Parrondo, Ricardo D , Riester, Kimberly, Tan, Melinda, Holmes, Lucy, Ansell, Stephen M. , Alkhateeb, Hassan B. , Hathcock, Matthew , Rosenthal, Allison , Murthy, Hemant S. , Johnston, Patrick B, Paludo, Jonas

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2740-2740

10.1158/1538-7445.am2026-2740 Get It

Abstract Large Language Models (LLM) are being widely adopted into the medical field for their impressive ability to analyze and summarize large amounts of text data. These models enable clinicians and researchers to extract meaningful insights from complex datasets and may assist with decision making. Here we present our workflows and application of LLM for the interpretation and summarization of clinical data related to CAR-T cell therapy. Using an LLM (Gemini 2.5 pro) in the Google Cloud Computing (GCP) environment, two applications were developed to analyze CAR-T cell therapy clinical data: 1) extracting and summarizing CRS and ICANS event-related data to streamline the compliance team workflow, and 2) identifying features available at time of CAR-T infusion able to classify patients into high- or low-monitoring needs 14 days post CAR-T. Patient data (vitals, labs, hematology notes, and EKGs) were extracted from the electronic medical record (EMR) using Google BigQuery into SQL tables in GCP. For each application, relevant data fields were retrieved, formatted into JSON objects, and embedded in the LLM prompt for context-aware processing. Both applications have undergone iterative prompt engineering after analyzing the LLM output against ground truth data in the EMR. For the application extracting and summarizing CRS and ICANS events, the LLM was optimized on Mayo Clinic Rochester data. When compared to the IEC compliance database, the LLM achieved 100% accuracy and F1 score for CRS events, and 96% accuracy and 82% F1 score for ICANS events. The match rate for CRS and ICANS grades were 83% and 89% respectively. We applied the same LLM to Mayo Clinic Arizona (MCA) and Mayo Clinic Florida (MCF) cases, who document clinical notes and toxicity flowsheet differently, and achieved an accuracy (MCA: 93%, MCF:93%) and F1 score (MCA: 96%, MCF: 96%) for CRS and accuracy (MCA: 81%, MCF:82%) and F1 score (MCA: 76%, MCF: 75%) for ICANS. LLM was able to capture events missed by manual reviews. For most of the discrepancies where compliance team final adjudication is needed, LLM will be updated to flag discrepancies for review by the compliance team. For the application related to the monitoring needs 14 days post CAR-T, the LLM identified 5 categories predictive of high or low monitoring needs post CAR-T infusion (disease status, inflammatory and tumor burden markers, hematologic status, renal function and performance status). Our model achieved a sensitivity of 85.7%, specificity of 23.8%, and F1 score of 65.5% for our first cohort, compared with data extracted by the LLM from the EMR. For our second cohort, with demographics statistically similar to cohort 1 and using the same 5 categories, the LLM achieved a sensitivity of 83.3%, a specificity of 28.6%, and F1 score of 65.4%. Our workflow and applications of LLM’s provide examples and guidance to others interested in applying LLM’s for clinical and research applications. Citation Format: Emmanuel Contreras Guzman, Matthew Jankowski, Andre De Menezes Silva Corraes, Malvika Gupta, Monica L. Shaw, Madiha Iqbal, Talal Hilal, Saurabh Chhabra, Ricardo Daniel Parrondo, Jody K. Mclean, Kim R. Riester, Kayla Joseph, Melinda Tan, Holly Ross, Cleyonia Barnett, Sylvia Carter, Semy Girmay, Rachel Wolan, Milana Ramsey, Christian Downhour, Kristy Morgan, Shae Sibley, Erica Rushing, Lucy Holmes, Allison Burgstahler, Stephen M. Ansell, Hassan Alkhateeb, Matthew Hathcock, Ramona Bruno, Allison C. Rosenthal, Hemant Murthy, Patrick B. Johnston, Jonas Paludo, Yi Lin. Applications of large language models to CAR-T cell therapy clinical data using Google cloud computing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2740.
Contemporary Perspectives on J‐Wave Syndromes: An Expert Consensus Statement
Nademanee, K., Wilde, Arthur A.M. , Ackerman, Michael J., Behr, Elijah R, Chen, P S, Chung, Fa Po, Coronel, R F M, Haissaguerre, Michel, Jiang, Chenyang, Khongphatthanayothin, Apichai , Makita, N., Morita, Hiroshi, Nakagawa, Hiroshi , Ngarmukos, Tachapong , Nogami, Akihiko, PAPPONE, CARLO, Priori, Silvia G., Rosso, Raphaël , Shimizu, W, Veerakul, Gumpanart, Makita, Naomasa , Behr, Elijah R. , Coronel, Ruben , Nademanee, Koonlawee , Nademanee, Koonlawee , Wilde, Arthur A M , Behr, Elijah Raphael , Chung, Fa Po , Coronel, Ruben , Makita, Naomasa , Morita, Hiroshi , Nakagawa, Hiroshi , Ngarmukos, Tachapong , Nogami, Akihiko , Shimizu, Wataru , Ackerman, Michael J. , Bezzina, Connie R. , Haissaguerre, Michel , Jiang, Chenyang , Juang, Jyh‐Ming Jimmy , Pappone, Carlo , Priori, Silvia G. , Viskin, Sami

Mayo Clinic

Journal of Arrhythmia | February 21, 2026 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/joa3.70284 | PMID 41738055 Get It

ABSTRACT J‐wave syndromes (JWS)—comprising Brugada syndrome (BrS) and early repolarization syndrome (ERS)—are important causes of malignant ventricular arrhythmias and sudden cardiac death in patients whose hearts appear structurally normal. Since the 2016 consensus, advances in genetics, pathophysiology, and therapy have redefined both understanding and management. BrS, once viewed as a purely electrical disorder, is now recognized along a microstructural–electrical continuum, with sodium‐channel dysfunction and subtle epicardial fibrosis of the right ventricular outflow tract as key contributors. Likewise, ERS—historically considered benign—carries significant risk when inferolateral J‐waves coexist with arrhythmic events. Genetically, SCN5A remains the sole gene with definitive disease association, while polygenic susceptibility materially modulates risk, underscoring complex inheritance. Risk stratification remains challenging: patients with prior cardiac arrest or arrhythmic syncope are highest risk, whereas asymptomatic individuals warrant multiparametric assessment integrating clinical features, ECG markers, electrophysiologic studies, and genetics. For decades, treatment centered on implantable cardioverter‐defibrillators and quinidine, both limited by availability, tolerance, and device complications. More recently, epicardial substrate ablation has emerged as a transformative therapy, with large registries and randomized trials demonstrating durable suppression of ventricular fibrillation and acceptable safety. This APHRS‐organized international consensus updates and extends the 2016 Expert Consensus and the 2022 ESC Guidelines, providing contemporary diagnostic frameworks, pragmatic risk‐stratification tools, and treatment algorithms for BrS and ERS. It emphasizes JWS as a microstructural–electrical disease spectrum and elevates substrate ablation as a major therapeutic advance, while outlining priorities for genetics, risk‐stratification and treatment algorithms.
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses
Han, Younghun , Byun, Jinyoung, Cooley, Matthew A. , Shaw, Vikram R., Ahmed, Fowsiyo , Giama, Nasra H., Ali, Hawa M. , Campbell, Nellie A. , Hassan, Mohamed, Andersen, Jesper B., Ankoma-Sey, Victor, Bañales, Jesús M. , Bujanda, L. , Bathe, Oliver F. , Bekaii-Saab, Tanios S., Borad, Mitesh J., Chan, Carlos H.F. , Cleary, S., Folseraas, Trine , Galle, P R, MacInnis, Robert J., Gores, Gregory J., Houlston, Richard S., Ilyas, Sumera, Javle, Milind, Johansen, Julia S., Christensen, Troels Dreier , Kamath, Ashwin S. , Kelley, Robin Kate , Lamarca, Angela, Lammert, F, Lindsey, Stacie , Macias, Rocio I. R., Patel, Tushar, Permuth, Jennifer B., Rossi, Stephen, Sanchez, William, Smoot, Rory L., Swerdlow, Anthony J., Cao, H. Tran, Valle, Juan, Weinmann, A., Wong, Linda L. , Zimmer, Vincent, Zhu, A., Kn, Lazaridis, Juran, Brian D., Jalal, Prasun Kumar, Knox, J., Hutchinson, Amy, Hicks, Belynda, Chanock, Stephen J., Hassan, Manal M. , Amos, Christopher I., McGlynn, Katherine A., Roberts, Lewis R., Roberts, Lewis R. , Sánchez, William , Han, Younghun , Byun, Jinyoung , Byun, Jinyoung , VanLith, Caitlin J. , Roberts, Lewis R , Banales, Jesus M , Jalal, Prasun K , Chan, Carlos H F , Sanchez, William , Shaw, Vikram R. , Hatia, Rikita , Andersen, Jesper B , Ankoma‐Sey, Victor, Bekaii‐Saab, Tanios , Borad, Mitesh J. , Björkström, Niklas K. , Cleary, Sean P. , Cornillet, Martin , Galle, Peter R., Genkinger, Jeanine M. , MacInnis, Robert J. , Gores, Gregory J. , Goyal, Lipika , Houlston, Richard S. , Ilyas, Sumera I. , Javle, Milind , Johansen, Julia S., Khan, Shahid Ali , Kim, Richard D. , Kwee, Sandi Alexander , Lamarca, Angela , LaRusso, Nicholas F. , Malhi, Harmeet , Permuth, Jennifer B. , Reeves, Helen L. , Smoot, Rory L. , Swerdlow, Anthony J , Weinmann‐Menke, Julia , Zhang, Xuehong , Zimmer, Vincent , Zhu, Andrew X. , Jalal, Prasun K. , Hutchinson, Amy , Hicks, Belynda , Koshiol, Jill , Chanock, Stephen Jacob , Amos, Christopher I. , McGlynn, Katherine A.

Mayo Clinic

Hepatology | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001699 | PMID 41627892 Get It

Background and Aims: Cholangiocarcinoma (CCA) is a rare but aggressive malignancy with poorly understood genetic susceptibility. To date, genome-wide association studies (GWAS) investigating germline variants associated with CCA risk remain limited. We aimed to identify genetic risk loci for CCA and its clinical subtypes through comprehensive GWAS and post-GWAS analyses. Approach and Results: We conducted a GWAS of 2366 CCA cases and 11,750 controls of European ancestry. Genome-wide significant loci ( p <5×10 −8 ) were identified and further examined through fine-mapping, functional annotation, and HLA imputation. Subgroup analyses were conducted by CCA subtypes and primary sclerosing cholangitis (PSC) status. Cross-trait linkage disequilibrium score regression and Mendelian randomization were employed to investigate the shared genetic architecture and potential causal relationships with a diverse range of traits. We identified 1 new genome-wide significant variant, rs535777 (OR=1.44), near HLA-DRB1/DQA1 associated with CCA, and 2 variants associated with extrahepatic CCA: rs116224263 (OR=0.17) in LINC02506 at 4p15.1 and rs6914950 (OR=1.63) near HLA-DRB1/DQB1 . Stratified analyses revealed rs2395184 (OR=3.51) near HLA-DRA/DRB5 associated with PSC-related CCA, and rs142674434 (OR=2.98) in THSD7A at 7p21.3 associated with non-PSC-related CCA. HLA imputation uncovered new amino acid residues associated with disease risk. Cross-trait analyses identified shared genetic signals between CCA and anthropometric, lipidemic, lifestyle, and medical traits. Mendelian randomization supported putative causal associations for 12 traits with CCA or its subtypes. Conclusions: Our large-scale GWAS highlights new genetic variants and HLA-linked mechanisms underlying CCA susceptibility. Integrating multi-step post-GWAS approaches enhances understanding of CCA pathogenesis and may facilitate the development of risk biomarkers for early detection and precision prevention strategies.
Through-Plane Forward Crosstalk in Superconducting Stripline Transmission Lines
Buhrow, Benjamin , Shaw, Stephen, Wa, Oldenburg, Haider, Clifton R.

Mayo Clinic

2025 IEEE 34th Conference on Electrical Performance of Electronic Packaging and Systems (EPEPS) | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-3

10.1109/epeps63858.2025.11346717 Get It

P-100. What is a Postoperative Spine Infection?
Matsuo, Takahiro, Gori, Andrea, Shaw, Jeremy D. , Berbari, Elie F. , Alavi, Seyed Mohammad Amin , Borgonovo, Fabio , Petri, Francesco , Matsuo, Takahiro , Tande, Aaron J.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.329 Get It

Abstract Background The increased frequency of spinal surgeries has led to a rise in postoperative spine infections (PSIs), now recognized as the third most common surgical complication. Currently, there is no standardized definition of PSI, complicating clinical management and research. This meta-epidemiological study aimed to develop clear diagnostic criteria to assist clinicians and researchers in identifying and reporting PSIs consistently. 2020 PRISMA flow diagram Sankey diagram showing the distribution of combination of criteria or definitions used by the authors. This refers to 21 articles that used a definition derived by the authors. Methods Following PRISMA guidelines, a comprehensive literature search was conducted by a medical librarian using Ovid MEDLINE (March 14, 2024). Studies were included if they reported on at least ten adult patients diagnosed with PSI and provided clear diagnostic definitions. The primary objective was to evaluate existing PSI diagnostic criteria and categorize them into thematic clusters. We constructed standardized diagnostic combinations using 13 predefined criteria derived from clinical practice guidelines and prior research (Table 1).Characteristics of the included studies*Total can be more than 100% since some variables can be present in multiple categories.This refers to 21 articles that used a definition derived by the authors. For articles #411 and #630 categorization was not possible as the definition provided only information about the depth of infection and not the criteria for diagnosis. Article #1148 was included as, defining “presumed aspetic” cases meant, by definition, also defining infectious cases.Abbreviations. The American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP), Centers for Disease Control and Prevention (CDC), The National Healthcare Safety Network (NHSN), Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA), Magnetic Resonance Imaging (MRI) Results From an initial 1,466 studies screened, 101 were included (Figure 1). Most studies were retrospective (91/101, 92.1%), and a majority (77/101, 76.2%) relied on established criteria such as those from the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) or the CDC. Seven studies combined predefined criteria with additional detailed explanations. Among the remaining studies using independent definitions, clinical signs and symptoms were the most common criteria (13/24, 54.2%) (Table 1). Criteria were grouped into clinical, microbiological, and radiological categories, with most studies primarily using clinical criteria alone or in combination with microbiological or imaging findings (Figure 2). Conclusion There was no clear consensus in the literature on what defines a PSI. Our findings emphasize the necessity of establishing a standardized PSI definition that integrates clinical, microbiological, and radiological criteria. Implementing such a unified framework could enhance diagnostic accuracy, address existing limitations associated with hardware complications, wound drainage interpretations, and imaging ambiguities, and improve upon the current shortcomings of surveillance systems. Disclosures Jeremy D. Shaw, MD, Globus: Grant/Research Support|Purgo Scientific: Advisor/Consultant|Purgo Scientific: Stocks/Bonds (Private Company)